Health & Fitness
Health and Fitness
Health and Fitness
Mon, January 19, 2009
Fri, January 16, 2009
Thu, January 15, 2009
Cobalis Corp Gets Federal Court Approval to Launch Its Flagship Anti-Allergy Product PreHistin"
LAGUNA BEACH, Calif.--([ BUSINESS WIRE ])--Cobalis Corp. (OTC:CLSC), a pharmaceutical biotech Company specializing in the development of anti-allergy medications, today announced the planned marketing launch of the flagship anti-allergy product PreHistin™ after approval in Federal Court in Santa Ana, CA on Jan. 13, 2009. The launch of PreHistin™ is scheduled for February 2009, and will enable the company to be discharged from Chapter 11.
Cobalis Corp. has conducted numerous clinical trials in over 30 board certified clinics with physicians throughout the U.S. with over 2200 patients in the Phase III trials of PreHistin™. The Company has demonstrated that pre seasonal treatment with PreHistin™ was seen to clearly reduce allergy symptoms without causing any side effects. The data from the clinical trials will enable Cobalis to launch PreHistin™ as a nutraceutical with clinical claims.
Cobalis Corp. has a manufacturing agreement with Monarch Nutraceuticals, a division of Nutraceutical Corp. (Nasdaq: NUTR) in Ogden, Utah, to manufacture and produce PreHistin™. Nutraceutical Corp. is the original manufacturer of PreHistin™ under the name Alleratin, which was distributed to thousands of allergy sufferers at no charge for compassionate use.
Chas Radovich, the CEO of Cobalis, said, "We are extremely proud to have reached the milestone of being able to launch PreHistin™, our flagship product in February 2009. The product will be available to the general public and to over 10,000 previous PreHistin™ users from the Phase III trials and allergy suffers who received compassionate use product over the years." Mr. Radovich went on to say, "We will finally be able to get our products to the over 50,000,000 allergy sufferers in the United States who have been waiting for a natural alternative to treat or prevent allergies."
ABOUT COBALIS CORP--PREHISTIN™
Headquartered in Laguna Beach, California, Cobalis Corp. is an over-the-counter pharmaceutical company. Its flagship product PreHistin™ is designed to prevent the primary causes of airborne allergies, and is set for launch in February 2009. The anti-allergy market is projected to exceed $10 Billion annually by 2010, and PreHistin™ is poised to capture significant market share. PreHistin™ is singularly positioned as it is the only Phase III clinically tested sublingual anti-allergy product with demonstrated efficacy.
PreHistin™, the "world's first pre-histamine," has shown in previous studies to modulate the body's level of protein IgE, reducing the overproduction of histamines, the primary cause of airborne allergy symptoms. Prior studies have shown that the active ingredient in PreHistin™ has essentially no risks or adverse effects to the general population including sedation and drowsiness found in most of the allergy products now available.
For more info please visit our website at [ www.Cobalis.com ].
Safe Harbor Statement:
Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as 'anticipate,' 'believe,' 'estimate,' 'expect,' 'intend' and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of the Company's products, the competitive environment within the industry, the ability of the Company to continue to expand its operations, the level of costs incurred in connection with the Company's expansion efforts, economic conditions in the industry and the financial strength of the Company's customers and suppliers. The Company does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.
